Background: About one-quarter of patients with advanced prostate cancer have alterations in homologous recombination repair (HRR) genes. In a global phase 3 study, talazoparib plus enzalutamide significantly improved progression-free survival in patients with HRR-deficient metastatic castration-resistant prostate cancer (mCRPC).
Objectives: This article reviews the role of oncology nurses and advanced practice providers (APPs) in administering talazoparib plus enzalutamide in patients with mCRPC.
Methods: This review and hypothetical case study illustrate the role of oncology nurses and APPs in the administration of talazoparib plus enzalutamide and the management of adverse events to ensure safe and effective use in clinical practice.
Findings: Oncology nurses and APPs play an important role in the dosing and administration of talazoparib plus enzalutamide and can recognize and manage adverse events in patients with HRR-deficient mCRPC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1188/24.CJON.483-491 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: In TALAPRO-2, the poly(ADP-ribose) polymerase inhibitor talazoparib plus the androgen receptor-signaling inhibitor enzalutamide improved radiographic progression-free survival (rPFS) versus placebo plus enzalutamide (hazard ratio [HR] = 0.63; 95% CI, 0.51-0.
View Article and Find Full Text PDFAn evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Expert Rev Anticancer Ther
December 2024
Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Introduction: Prostate cancer (PCa) is the second most common cancer diagnosis among men worldwide, with poor prognosis in its advanced stage. Treatment strategies have evolved, including the use of androgen receptor pathway inhibitors (ARPIs) and poly (ADP-ribose) polymerase inhibitors (PARPis).
Areas Covered: This review evaluates the clinical efficacy, safety, and future potential of combining talazoparib, a potent PARPi, with enzalutamide, a strong androgen receptor (AR) antagonist.
Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison.
Prostate Cancer Prostatic Dis
December 2024
EVERSANA™, Burlington, ON, Canada.
Background: Without head-to-head trials between talazoparib+enzalutamide (TALA + ENZA), olaparib+abiraterone acetate (OLAP + AAP), and niraparib plus AAP (NIRA + AAP) the ability to evaluate their relative efficacy as first-line (1 L) treatment in metastatic castration-resistant prostate cancer (mCRPC) is limited. The objective of this study was to assess the relative efficacy between TALA + ENZA (TALAPRO-2) versus OLAP + AAP (PROpel) and NIRA + AAP (MAGNITUDE) in 1 L mCRPC via a matching-adjusted indirect treatment comparison (MAIC).
Methods: Patient-level data from TALAPRO-2 and published data from PROpel and MAGNITUDE were used.
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study.
Eur J Cancer
December 2024
Huntsman Cancer Institute (NCI-CCC), University of Utah, Salt Lake City, UT, USA.
Article Synopsis
The TALAPRO-3 study design: a plain language summary.
Future Oncol
October 2024
Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France.
Article Synopsis
- The TALAPRO-3 study investigates the effectiveness of combining two cancer treatments, talazoparib and enzalutamide, for patients with metastatic castration-sensitive prostate cancer (mCSPC), involving 599 participants from 27 countries.
- mCSPC is a type of prostate cancer that has spread to other parts of the body and responds to treatments that lower testosterone levels.
- The study aims to determine if the combination of talazoparib and enzalutamide improves survival without disease progression compared to a placebo with enzalutamide, while also assessing side effects, overall health, and quality of life among patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!